- Home
- HPAI vs CMPX Comparison
HPAI vs CMPX Comparison
Compare HPAI & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- CMPX
- Stock Information
- Founded
- HPAI 2023
- CMPX 2014
- Country
- HPAI Singapore
- CMPX United States
- Employees
- HPAI N/A
- CMPX N/A
- Industry
- HPAI
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- HPAI
- CMPX Health Care
- Exchange
- HPAI NYSE
- CMPX Nasdaq
- Market Cap
- HPAI 235.6M
- CMPX 206.3M
- IPO Year
- HPAI N/A
- CMPX N/A
- Fundamental
- Price
- HPAI $6.43
- CMPX $1.42
- Analyst Decision
- HPAI
- CMPX Strong Buy
- Analyst Count
- HPAI 0
- CMPX 3
- Target Price
- HPAI N/A
- CMPX $7.67
- AVG Volume (30 Days)
- HPAI 18.2K
- CMPX 421.2K
- Earning Date
- HPAI 12-31-2024
- CMPX 11-12-2024
- Dividend Yield
- HPAI N/A
- CMPX N/A
- EPS Growth
- HPAI N/A
- CMPX N/A
- EPS
- HPAI N/A
- CMPX N/A
- Revenue
- HPAI $29,575,625.00
- CMPX $850,000.00
- Revenue This Year
- HPAI N/A
- CMPX N/A
- Revenue Next Year
- HPAI N/A
- CMPX $610.48
- P/E Ratio
- HPAI $32.37
- CMPX N/A
- Revenue Growth
- HPAI 132.36
- CMPX N/A
- 52 Week Low
- HPAI $3.07
- CMPX $0.77
- 52 Week High
- HPAI $14.74
- CMPX $2.34
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- CMPX 41.28
- Support Level
- HPAI N/A
- CMPX $1.44
- Resistance Level
- HPAI N/A
- CMPX $1.58
- Average True Range (ATR)
- HPAI 0.00
- CMPX 0.12
- MACD
- HPAI 0.00
- CMPX -0.01
- Stochastic Oscillator
- HPAI 0.00
- CMPX 11.63
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to broadly drug the immune system and identify optimal combinations empirically. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of three product candidates, CTX-009, CTX-471, and CTX-8371.